Global state: clinically important change in global state · patients with schizophrenia
It is very uncertain whether chlorpromazine changes global state: clinically important change ‐ as defined by each of… compared with piperacetazine (very low certainty).
1 finding from 1 review
Mental state: overall mean change score (BPRS total, high = poor)* · patients with schizophrenia
1 finding from 1 review
Clinically important change in negative symptoms · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events: incidence of adverse effects ‐ as defined by each of the studies · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects/events: incidence of adverse effects ‐ as defined by… compared with piperacetazine (very low certainty).
1 finding from 1 review
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects/events: clinically important movement disorder… compared with piperacetazine (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
1 finding from 1 review
Costs · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global State: clinically important improvement · patients with schizophrenia
It is very uncertain whether chlorpromazine changes global state: clinically important improvement Clinical Global… compared with metiapine (very low certainty).
2 findings from 1 review
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects. Specific: movement disorders ‐ parkinsonism compared with metiapine (very low certainty).
1 finding from 1 review
Service use: readmission due to relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction of participant or care provider with treatment · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: aggressive or violent behaviour · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: clinically important change in global state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: 1a. General symptoms ‐ average change (PANSS, short term) · patients with schizophrenia
1 finding from 1 review
Mental state: 2c. Specific ‐ average change score for negative symptoms (PANSS ‐ negative short term) · patients with schizophrenia
1 finding from 1 review
Adverse effects: incidence of serious adverse effects. Movement disorders ‐ dyskinesia ‐short‐term · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects: incidence of serious adverse effects. Movement… compared with clotiapine (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found